A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07198321 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 450 participants, started 2025-09-22 and due to reach its primary completion in 2027-09-22. Interventions recorded: GFH276. Conditions listed: Cancer; PDAC; CRC (Colorectal Cancer); NSCLC. Primary outcome: Phase Ia:The incidence and severity of AEs and SAEs; Phase Ia:The incidence of DLT events; Phase Ib:The incidence and severity of AEs and SAEs. Sites: China. No results are recorded here; the registry entry is the source.